Citation

Traish AM, Mulgaonkar A, Giordano N. Korean J. Urol. 2014; 55(6): 367-379.

Copyright

(Copyright © 2014, Korean Urological Association)

DOI

10.4111/kju.2014.55.6.367

PMID

unavailable

Abstract

With aging, abnormal benign growth of the prostate results in benign prostate hyperplasia (BPH) with concomitant lower urinary tract symptoms (LUTS). Because the prostate is an androgen target tissue, and transforms testosterone into 5α-dihydrotestosterone (5α-DHT), a potent androgen, via 5α-reductase (5α-R) activity, inhibiting this key metabolic reaction was identified as a target for drug development to treat symptoms of BPH. Two drugs, namely finasteride and dutasteride were developed as specific 5α-reductase inhibitors (5α-RIs) and were approved by the U.S. Food and Drug Administration for the treatment of BPH symptoms. These agents have proven useful in the reducing urinary retention and minimizing surgical intervention in patients with BPH symptoms and considerable literature exists describing the benefits of these agents. In this review we highlight the adverse side effects of 5α-RIs on sexual function, high grade prostate cancer incidence, central nervous system function and on depression. 5α-Rs isoforms (types 1-3) are widely distributed in many tissues including the central nervous system and inhibition of these enzymes results in blockade of synthesis of several key hormones and neuro-active steroids leading to a host of adverse effects, including loss of or reduced libido, erectile dysfunction, orgasmic dysfunction, increased high Gleason grade prostate cancer, observed heart failure and cardiovascular events in clinical trials, and depression. Considerable evidence exists from preclinical and clinical studies, which point to significant and serious adverse effects of 5α-RIs, finasteride and dutasteride, on sexual health, vascular health, psychological health and the overall quality of life. Physicians need to be aware of such potential adverse effects and communicate such information to their patients prior to commencing 5α-RIs therapy. © The Korean Urological Association, 2014.

Language: en

Keywords

human; Depression; quality of life; depression; anxiety; suicide attempt; heart failure; review; epilepsy; sexual dysfunction; Alzheimer disease; electrostimulation; side effect; erectile dysfunction; prostate cancer; cancer incidence; dutasteride; finasteride; libido disorder; prostate hypertrophy; androstanolone; ejaculation disorder; mean arterial pressure; lower urinary tract symptom; Gleason score; 5a-reductase inhibitors; alfaxalone; intraoperative floppy iris syndrome; Physiological sexual dysfunction; Prostate neoplasms; prostate volume; steroid 5alpha reductase; streptavidin